Dateline City:
SAN ANTONIO
Collaborative Trial is First to Investigate an Anti-PD-1 Therapy, Pembrolizumab, Combined with Trastuzumab
Study to Explore Whether New Approach May Reverse Trastuzumab Resistance in Cancer with Significant Unmet Need
SAN ANTONIO--(BUSINESS WIRE)--The International Breast Cancer Study Group (IBCSG), Breast
International Group (BIG), and Merck, known as MSD outside the United
States and Canada, today announced the opening of the PANACEA study, a
global collaborative study exploring a new way to treat HER2+ breast
cancer that has become resistant to the current standard of care.
Language:
English
Contact:
International Breast Cancer Study GroupLaura Cava Northrop, 617-632-3973press@ibcsg.orgorBreast International GroupCecilia Waldvogel, +41 79 478-0238cecilia.waldvogel@BIGagainstbc.orgorMerckClaire Mulhearn, 908-236-1118claire.mulhearn@merck.com
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more